COLL Stock News & Catalysts – Collegium Pharmaceutical

FEATURED

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS® Quarterly Net

Summary

Nov 5, 2026, 7:30 AM ·Globe Newswire

RECENT

Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

STOUGHTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Oct 29, 2026, 8:00 AM ·Globe Newswire

Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026

STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Oct 22, 2026, 8:00 AM ·Globe Newswire

Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses

STOUGHTON, Mass., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Oct 21, 2026, 8:00 AM ·Globe Newswire

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Oct 6, 2026, 8:00 AM ·Globe Newswire

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Sep 8, 2026, 8:00 AM ·Globe Newswire

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Aug 13, 2026, 7:30 AM ·Globe Newswire

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM®

Aug 6, 2026, 7:30 AM ·Globe Newswire

Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026

STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often

Jul 23, 2026, 8:00 AM ·Globe Newswire

Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston

STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood

Jul 20, 2026, 8:00 AM ·Globe Newswire

Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026

Jun 5, 2026, 8:00 AM ·Globe Newswire

Collegium to Participate in 2026 Jefferies Global Healthcare Conference

STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare

May 27, 2026, 8:00 AM ·Globe Newswire

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection

May 12, 2026, 7:31 AM ·Globe Newswire

Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of

May 7, 2026, 7:30 AM ·Globe Newswire

Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7,

Apr 23, 2026, 8:00 AM ·Globe Newswire

Collegium Pharmaceutical, Inc. COLL · News